Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02381886 · ClinicalTrials.gov registry record · Phase 1
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase 1 study of Advanced Malignancies That Harbor IDHR132 Mutations, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
- 16
- Study locations
NCT02381886 is a Phase 1 study of Advanced Malignancies That Harbor IDHR132 Mutations that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 166 participants. The trial reports 16 study locations across 10 states.
The verdict
NCT02381886, a Phase 1 study of Advanced Malignancies That Harbor IDHR132 Mutations, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
- 16
- Study locations
Study Summary
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
Conditions Studied
Interventions
- DRUG IDH305
Study Locations (16)
Other
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Heidelberg
- ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55 - Rotterdam
- Novartis Investigative Site - Singapore
Massachusetts
- Dana Farber Cancer Institute SC (1) - Boston
- Dana Farber Cancer Institute - Boston
New York
- Columbia University Medical Center- New York Presbyterian Onc Dept. - New York
- Columbia University Medical Center - New York
Victoria
- Novartis Investigative Site - Melbourne
- Novartis Investigative Site - Parkville
Texas
- Uni Of TX MD Anderson Cancer Cntr - Houston
Ontario
- Novartis Investigative Site - Toronto
North Rhine-Westphalia
- Novartis Investigative Site - Cologne
Thuringia
- Novartis Investigative Site - Jena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2015-03-06 |
| Est. Completion | 2027-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02381886
The ClinicalTrials.gov registry entry for NCT02381886 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Malignancies That Harbor IDHR132 Mutations appearing as the primary indexed condition, and to 1 intervention - of which IDH305 is the first listed.
NCT02381886 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Other, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT02381886 about?
NCT02381886 is a clinical study titled "A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations". A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
What is the current status of trial NCT02381886?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2015-03-06. Estimated completion is 2027-02-10.
What conditions does trial NCT02381886 study?
This clinical trial studies the following conditions: Advanced Malignancies That Harbor IDHR132 Mutations.
What interventions are being tested in trial NCT02381886?
The interventions under investigation include: IDH305 (DRUG).
Who is sponsoring clinical trial NCT02381886?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02381886 being conducted?
This trial has 16 study locations across Massachusetts, New York, Texas, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.